Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reiterated by Oppenheimer Holdings, Inc. in a research note issued on Monday.

TEVA has been the topic of several other reports. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating and set a $32.27 price objective on the stock in a report on Wednesday, June 28th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $38.00 price objective (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a report on Monday, May 15th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $21.00 price objective (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, August 31st. BTIG Research upgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Monday. Finally, Piper Jaffray Companies restated a “neutral” rating and issued a $23.00 price target (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, August 4th. Five equities research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $32.65.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 19.33 on Monday. The company has a 50-day moving average of $20.60 and a 200-day moving average of $28.94. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $52.66. The firm’s market capitalization is $19.64 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period last year, the company posted $1.25 earnings per share. The business’s revenue was up 12.9% compared to the same quarter last year. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/13/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. San Francisco Sentry Investment Group CA bought a new position in Teva Pharmaceutical Industries Limited in the 2nd quarter valued at approximately $106,000. Bronfman E.L. Rothschild L.P. raised its holdings in Teva Pharmaceutical Industries Limited by 7.8% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC raised its holdings in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC bought a new position in Teva Pharmaceutical Industries Limited in the 1st quarter valued at approximately $123,000. Finally, Sterling Investment Advisors Ltd. raised its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 56.87% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply